Revolutionary cancer treatment demonstrates potential for Almavid™ Drug Candidate application in solid tumors.
London (UK) May 28th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments.
Vidac Pharma, a clinical-stage biopharmaceutical company developing first-in-class cancer therapeutics, today announced promising real-world pharmacokinetics results from the use of its investigational drug Almavid™, a proprietary subcutaneous formulation of VDA 1102 (Tuvatexib), in pediatric brain cancer patients.
Administered to three pediatric patients with brain cancer, Almavid™ demonstrated exceptional pharmacokinetic properties, including high blood stability for over 24 hours, strong dose linearity, and sustained blood concentration levels across patients. These findings suggest that Almavid™ has strong potential as a broad-spectrum treatment for solid tumors, both as a monotherapy and in combination therapies.
VDA 1102, the active ingredient in Almavid™, targets a fundamental mechanism in cancer metabolism by reversing the Warburg effect—a hallmark of cancer cell behavior first described by Nobel laureate Otto Warburg nearly a century ago. Unlike healthy cells, cancer cells exhibit heightened glycolysis even in the presence of oxygen. While this phenomenon has primarily been leveraged in diagnostics (e.g., PET scans), Vidac Pharma is the first company to translate this biological insight into a targeted therapeutic strategy.
VDA 1102 works by disrupting the binding of hexokinase 2 (HK2), an enzyme overexpressed in cancer cells, to the mitochondrial voltage-dependent anion channel (VDAC1). This interaction blocks the natural process of programmed cell death (apoptosis), allowing cancer cells to persist and proliferate. By modifying HK2’s structure, VDA 1102 re-enables apoptosis, restoring normal cellular metabolism and promoting cancer cell death while modifying Tumor microenvironment to pro immune.
This mechanism has already shown clinical promises. VDA 1102 previously demonstrated efficacy with minimal side effects in Phase 2 trials targeting two oncological skin conditions: Actinic Keratosis and Cutaneous T-Cell Lymphoma.
“These latest results in our proprietary new formulation for Subcutaneous injections in pediatric patients highlight VDA 1102’s potential to become a transformational agent across a broad range of solid tumors,” said Dr Max Herzberg, Chairman of Vidac Pharma . “We are optimistic about advancing Almavid™ into larger trials as we continue our mission to make cancer cells mortal again.”
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), and in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.